SenzaGen AB
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SENZA.ST research report →
Companysenzagen.com
SenzaGen AB develops, performs, and sells non-animal tests for assessing a substance's allergenicity. The company offers genomic allergen rapid detection (GARD)skin, an in vitro test to identify potential chemical skin sensitizers; GARDpotency, an in vitro add-on test to GARDskin for potency classification; GARDskin Dose-response, an in vitro test for quantitative skin sensitizing potency assessment of chemicals; and GARDair, an in vitro test for identifying chemical respiratory sensitizers, as well as GARDskin medical device, an in vitro skin sensitization testing for medical devices and solid materials. It also provides irritation and corrosion testing services.
- CEO
- Peter Nahlstedt
- IPO
- 2017
- Employees
- 34
- HQ
- Lund, SE
Price Chart
Valuation
- Market Cap
- $174.24M
- P/E
- -12.27
- P/S
- 2.94
- P/B
- 1.84
- EV/EBITDA
- -14.11
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 63.42%
- Op Margin
- -26.08%
- Net Margin
- -23.22%
- ROE
- -17.20%
- ROIC
- -13.77%
Growth & Income
- Revenue
- $57.97M · 0.48%
- Net Income
- $-11,587,000 · 35.09%
- EPS
- $-0.39 · 40.00%
- Op Income
- $-11,498,000
- FCF YoY
- 27.44%
Performance & Tape
- 52W High
- $6.84
- 52W Low
- $4.60
- 50D MA
- $5.26
- 200D MA
- $5.77
- Beta
- 0.54
- Avg Volume
- 21.86K
Get TickerSpark's AI analysis on SENZA.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SENZA.ST Coverage
We haven't published any research on SENZA.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SENZA.ST Report →